These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9589671)

  • 21. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of short-term insulin-like growth factor-I or growth hormone treatment on bone turnover, renal phosphate reabsorption and 1,25 dihydroxyvitamin D3 production in healthy man.
    Bianda T; Hussain MA; Glatz Y; Bouillon R; Froesch ER; Schmid C
    J Intern Med; 1997 Feb; 241(2):143-50. PubMed ID: 9077371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a growth hormone receptor antagonist on bone markers in acromegaly.
    Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults.
    Bianda T; Glatz Y; Bouillon R; Froesch ER; Schmid C
    J Clin Endocrinol Metab; 1998 Jan; 83(1):81-7. PubMed ID: 9435420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
    Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
    Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects.
    Amato G; Izzo G; La Montagna G; Bellastella A
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):27-32. PubMed ID: 8796135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
    Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
    Toogood AA; Shalet SM
    J Clin Endocrinol Metab; 1999 Jan; 84(1):131-6. PubMed ID: 9920073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group.
    Longobardi S; Keay N; Ehrnborg C; Cittadini A; Rosén T; Dall R; Boroujerdi MA; Bassett EE; Healy ML; Pentecost C; Wallace JD; Powrie J; Jørgensen JO; Saccà L
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1505-12. PubMed ID: 10770189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of growth hormone replacement therapy on markers of bone formation and bone mineral density in elderly men].
    Kozakowski J; Papierska L; Krassowski J; Zgliczyński S
    Pol Arch Med Wewn; 1998 Oct; 100(4):306-12. PubMed ID: 10335039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The GH-releasing effect of Hexarelin, a synthetic hexapeptide, in newborns is lower than in young adults.
    Bartolotta E; Bellone J; Aimaretti G; Arvat E; Benso L; Deghenghi R; Camanni F; Ghigo E
    J Pediatr Endocrinol Metab; 1997; 10(5):491-7. PubMed ID: 9401905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.
    Holloway L; Butterfield G; Hintz RL; Gesundheit N; Marcus R
    J Clin Endocrinol Metab; 1994 Aug; 79(2):470-9. PubMed ID: 7519191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study.
    Hansen TB; Brixen K; Vahl N; Jørgensen JO; Christiansen JS; Mosekilde L; Hagen C
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3352-9. PubMed ID: 8784096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion.
    Andersson B; Swolin-Eide D; Magnusson P; Albertsson-Wikland K
    Clin Endocrinol (Oxf); 2015 Jan; 82(1):91-9. PubMed ID: 24818653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
    Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of therapy with recombinant human growth hormone on insulin-like growth factor system components and serum levels of biochemical markers of bone formation in children after severe burn injury.
    Klein GL; Wolf SE; Langman CB; Rosen CJ; Mohan S; Keenan BS; Matin S; Steffen C; Nicolai M; Sailer DE; Herndon DN
    J Clin Endocrinol Metab; 1998 Jan; 83(1):21-4. PubMed ID: 9435411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.